Type 2 Diabetes Clinical Trial
Official title:
A Pilot Study Investigating the Effects of the Combined Effects of Cocoa and Soy Polyphenols in a Soy Protein Matrix on Insulin Resistance and Cardiovascular Disease Risk in Type 2 Diabetes - A Randomised Placebo-Controlled Double-Blind Parallel Study
Diabetes is an increasingly common condition affecting millions of people world wide. The
cornerstone of treatment is lifestyle that includes looking at the way how people eat. It is
known that food containing compounds called polyphenols can reduce the risk of heart disease
risk in people with diabetes. Two foods that are rich sources of polyphenols are cocoa
(epicatechins) and soy (isoflavones). Previous studies have shown the benefits of these foods
in the diets of people with diabetes. It has also been shown that soy isoflavones and cocoa
polyphenols can improve the mood in certain groups of patients.
What is not known is whether there is any extra benefit of combining soy protein and
isoflavones with cocoa.
The aim of the study is to look at the modification of cardiovascular risk by soy and/or
cocoa in patients with type 2 diabetes, alone or in combination.
1. General information about the study
The target number of participants is 100. All participants are patients with type 2
diabetes on diet alone or metformin treatment. Participants will be asked to eat two soy
bars daily for 8 weeks. The length of the study is 10 weeks and involves 4 visits at the
Diabetes Research Centre in Hull, UK.
The bars will contain:
- soy protein alone, or
- soy protein with additional isoflavones, or
- soy protein with cocoa, or
- soy protein with isoflavones and cocoa, or
- placebo bars without soy protein, isoflavones or cocoa.
The study is randomised (a computer based allocation schema will be used to decide which
bars the participant will need to consume). Participants have the same 20% chance to be
participant of any of the above groups. The study is placebo-controlled (there is one
arm of placebo bars without soy protein, additional isoflavones or cocoa). The study is
double-blind (neither the participants or the research team will know which bars they
will take).
2. Study-specific procedures
Visit 1 (week 0). Non-fasting visit. Interested participants discuss the study with a member
of the study team who will explain each aspect of the study, following which informed consent
will be then obtained. Subsequently, blood pressure, weight, height and waist circumference
will be measured, medical history and list of medication are recorded, and blood is taken to
determine eligibility. A dietitian will explain about eating a normal diet and the foods we
would like the participants to avoid during the study. Vegetarian patients may include too
much soy in the diet and for this reason they will not be able to take part in the study. All
participants will be non smokers.
Visit 2 (week 2)and Visit 4 (week 10). Fasting visits. Fasting blood is taken and the EndoPAT
is performed. Weight, height and waist circumference measurement performed. The EndoPAT test
takes between 20-30 minutes. The first box of study bars is dispensed during visit 2.
Participants need to consume two bars daily. All remaining uneaten bars and empty wrappers
will be collected during visit 4.
Visit 3 (week 6). Non-fasting visit. Height, weight, abdominal circumference, blood pressure
are measured. Second box of study bars is dispensed.
Participants are asked to complete a one week food diary and a three day hunger questionnaire
before the fasting blood tests. The food diary includes mood rating scales to assess the
effect of the consumption of the bars on mood. Participants need to complete these prior to
Visit 2 and visit 4.
Participants have 24 hours blood pressure measurement prior to Visit 2 and Visit 4.
24 hours urine collection also takes place prior to visit 2 and visit 4.
3. Optional test incorporated into the study: Body Volume Index measurement Based on
participants preference, Body Volume Index measurement is offered as a complementary tool to
assess body shape and weight.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |